

IN THE CLAIMS:

1-3 (withdrawn)

4. (re-presented and amended) A polynucleotide encoding ~~the~~ ^a polypeptide according to any one of the claims 1 to 3 selected from:

(a) a polypeptide comprising a CR-50 antibody recognition site of Reelin protein, and not containing an F-spondin domain or a repeat site, wherein the polypeptide is derived from a mouse Reelin polypeptide;

(b) a polypeptide comprising an amino acid sequence shown in SEQ ID NO:2, and not containing an F-spondin domain or a repeat site; and

(c) the polypeptide of (a) or (b) comprising a deletion, substitution, or addition of one or more amino acid; ^a ₂

(d) a polypeptide encoded by a degenerative nucleic acid sequence of the polypeptides of any of (a) to (c); and

wherein the polypeptide binds to antibody CR-50.

5. (amended) A polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 1 and not containing a nucleotide sequence encoding an F-spondin domain or a repeat domain, wherein the polypolynucleotide encodes a polypeptide that binds a CR-50 antibody;

a²

(b) a polynucleotide encoding a polypeptide capable of binding to a CR-50 antibody, ~~which wherein the polynucleotide~~ comprises deletion, substitution, or addition of one or more nucleotides in the nucleotide sequence shown in SEQ ID NO: 1, ~~and wherein the encoded polypeptide does not contain an F-spondin domain or a repeat site; and~~

(c) a polynucleotide comprising a degenerate nucleotide sequence of ~~the polynucleotide polypeptide of (a) or-(b).~~

6. (original) An expression vector comprising the polynucleotide according to claim 4 or 5.

7. (original) A host cell transfected with the expression vector according to claim 6.

8. (amended) A method for producing ~~the-a polypeptide according to any one of claims 1 to 3~~, which comprises culturing the host cell according to claim 7.

9. (withdrawn)

10. (amended) A composition for stimulating the assembly of Reelin protein molecules, which comprises ~~the polypeptide according to any one of claims 1 to 3 or~~ the polynucleotide according to claim 4 or 5.

11. A pharmaceutical composition for diagnosis and/or treatment of diseases resulting from abnormally positioned neurons, which comprises ~~the polypeptide according to any one of claims 1 to 3 or~~ the polynucleotide according to claim 4 or 5.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com